New pill could tame Hormone-Driven high blood pressure

NCT ID NCT07550465

Not yet recruiting Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called QLS1410 for people with primary aldosteronism, a condition where the adrenal glands make too much aldosterone, causing high blood pressure. The trial will compare the drug to a placebo in 60 adults to see if it safely lowers blood pressure over 12 weeks. Participants must stop certain other blood pressure medications during the study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLS1410 tablet
What this could lead to: If successful, this could provide a new treatment option for people with primary aldosteronism to better control their blood pressure.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY ALDOSTERONISM

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.